Pay in 4 interest-free payments of $6.89 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
Why it was included in the FDA ban The FDA cites significant safety risks due to the potential for congestive heart failure in certain patients seen in a clinical trial that was terminated
During the critical 24-hour period following the injury, the observations hinted a minimal mortality rate in the BPC-157 group
LXs Targets The family of LXs, like LXA4 and LXB4, generated from arachidonic acid display anti-inflammatory activities
Certificates of Analysis are available to verified visitors
Protocol Used: 0.25 mg BPC-157 subcutaneous injection daily for 6 weeks, administered 2 inches proximal to Achilles insertion point, combined with eccentric heel drops and gradual return to running
